GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » WACC %

CalciMedica (CalciMedica) WACC % :9.19% (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CalciMedica WACC %?

As of today (2024-05-14), CalciMedica's weighted average cost of capital is 9.19%%. CalciMedica's ROIC % is -5373.27% (calculated using TTM income statement data). CalciMedica earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


CalciMedica WACC % Historical Data

The historical data trend for CalciMedica's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CalciMedica WACC % Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
WACC %
Get a 7-Day Free Trial - 6.93 7.52 8.58 6.14

CalciMedica Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.58 8.96 9.01 9.17 6.14

Competitive Comparison of CalciMedica's WACC %

For the Biotechnology subindustry, CalciMedica's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CalciMedica's WACC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's WACC % distribution charts can be found below:

* The bar in red indicates where CalciMedica's WACC % falls into.



CalciMedica WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, CalciMedica's market capitalization (E) is $59.608 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2023, CalciMedica's latest one-year quarterly average Book Value of Debt (D) is $5.36 Mil.
a) weight of equity = E / (E + D) = 59.608 / (59.608 + 5.36) = 0.9175
b) weight of debt = D / (E + D) = 5.36 / (59.608 + 5.36) = 0.0825

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.441%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. CalciMedica's beta is 0.93.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.441% + 0.93 * 6% = 10.021%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Dec. 2023, CalciMedica's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $5.36 Mil.
Cost of Debt = -0 / 5.36 = 0%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -34.357 = 0%.

CalciMedica's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9175*10.021%+0.0825*0%*(1 - 0%)
=9.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CalciMedica  (NAS:CALC) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CalciMedica's weighted average cost of capital is 9.19%%. CalciMedica's ROIC % is -5373.27% (calculated using TTM income statement data). CalciMedica earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

CalciMedica (CalciMedica) Business Description

Traded in Other Exchanges
N/A
Address
274 Redwood Shores Parkway, P.O. Box 144, Redwood City, CA, USA, 94065
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Executives
Robert N Wilson director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
A. Rachel Leheny director, 10 percent owner, officer: Chief Executive Officer C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Eric W Roberts director, 10 percent owner, officer: Chief Business Officer VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar officer: Chief Medical Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Fred A Middleton director, 10 percent owner 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p. 10 percent owner 1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Co Investment Fund Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn officer: President and COO C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman officer: Chief Scientific Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037